2 registrations that name tetracosactide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
2US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT04546126
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
Early phase 1
Benjamin Viglianti
About 24 people
Started Nov 1, 2021
In plain words An early phase 1 study of tetracosactide in people 18 and older, run by Benjamin Viglianti. It plans to enroll about 24 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Radiotracer; Hypertension; Cholesterol.
Participants without any known adrenal pathology as normal controls for undergoing endocrine manipulation
The exclusion criteria are on the listing.
What it tests, as registered
Dexamethasone (Group 2); Cosyntropin (Group 3); PET/CT Scan with FNP-59
Registered summary
This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.
Where, as registered
2 US sites in 1 state.
RecruitingNCT03514589
NeSST2: The Development of a Noninvasive Short Synacthen Test
Phase 2
Sheffield Children's NHS Foundation Trust
About 12 people
Started Oct 12, 2012
In plain words A Phase 2 study of tetracosactide in male participants 6 months to 60, run by Sheffield Children's NHS Foundation Trust. It plans to enroll about 12 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 6 months to 60; healthy volunteers accepted. Conditions: Adrenal Suppression.
Healthy, male volunteers aged between 18-64 with none of the exclusion criteria listed below.
Healthy children of either sex, aged between 2 and 15 years (up to their 16th birthday) with none of the exclusion criteria listed below.
Healthy children of both sexes, aged between 0-18 years without exclusion criteria 1,2,3,5,6,7,8,9,10,11,12,14 listed below.
Asthmatic children of both sexes, aged between 6 months and 15 years, prescribed regular inhaled corticosteroids and without exclusion criteria 1,5,9,10,11,12, and 14 listed below.
The exclusion criteria are on the listing.
What it tests, as registered
nasal Tetracosactide; IV tetracosactide
Registered summary
Recently there has been concern about the effect of inhaled steroids, routinely used in the treatment of asthma, on the body's ability to produce its natural stress hormone cortisol. Failure of adequate cortisol production in times of stress e.g. illness, can result in serious illness or death. Patients receiving longterm steroid treatment may have reduced levels of cortisol and not be able to produce adequate amounts in times of need, a process called adrenal suppression. The full summary is on the listing.